114
Trials as lead sponsor
Most active programmes
The drugs appearing most often across Moderna's recently active trials. Comparator arms are excluded.
- mRNA-127313 trials
- mRNA-134513 trials
- mRNA-101012 trials
- mRNA-16479 trials
- mRNA-1273.2147 trials
- mRNA-12834 trials
Upcoming readouts
Next primary completion dates among Moderna's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.
Top therapeutic areas
Conditions studied most often across Moderna's recently active trials.
- SARS-CoV-229 trials
- Respiratory Syncytial Virus11 trials
- Influenza11 trials
- Seasonal Influenza8 trials
- Cytomegalovirus Infection6 trials
- COVID-195 trials
Moderna pipeline by phase
The main study drugs across 25 active trials Moderna leads on ClinicalTrials.gov. Each drug sits in the highest phase among its currently active trials, which can be lower than a phase it has already completed.
Phase 32 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| mRNA-1403 | 2 | — | Sept 2026 est. | NCT06592794 · NCT05992935 |
| mRNA-1018-H5 | 1 | — | Jan 2027 est. | NCT07496450 |
Phase 25 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| mRNA-4157 | 2 | — | Nov 2027 est. | NCT03897881 · NCT03313778 |
| mRNA-1195 | 1 | 1 | Jan 2029 est. | NCT06735248 |
| mRNA-1283 | 1 | — | Aug 2029 est. | NCT07808697 |
| mRNA-1647 | 1 | — | Mar 2027 est. | NCT05683457 |
| mRNA-1982 | 1 | — | Nov 2028 est. | NCT07561294 |
Phase 112 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| mRNA-1189 | 2 | 1 | Oct 2026 est. | NCT07478952 · NCT05164094 |
| mRNA-3927 | 2 | 2 | Aug 2027 est. | NCT05130437 · NCT04159103 |
| mRNA-0184 | 1 | 1 | Dec 2026 est. | NCT06655870 |
| mRNA-1195.1 | 1 | — | Oct 2026 est. | NCT05831111 |
| mRNA-1345 | 1 | — | Aug 2029 est. | NCT05743881 |
| mRNA-1365 (Profile 2) | 1 | 1 | Jul 2027 est. | NCT07764237 |
| mRNA-1469 | 1 | 1 | Sept 2027 est. | NCT07737717 |
| mRNA-2808 | 1 | 1 | Jun 2030 est. | NCT07116616 |
| mRNA-3705 | 1 | 1 | Apr 2034 est. | NCT05295433 |
| mRNA-3745 | 1 | — | Nov 2026 est. | NCT05095727 |
| mRNA-4106 | 1 | 1 | Aug 2027 est. | NCT06880549 |
| mRNA-4359 | 1 | 1 | Feb 2032 est. | NCT05533697 |
Phase 42 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| mRNA-1273 | 1 | — | Jun 2027 est. | NCT07266558 |
| mRNA-1273 Variant-containing Formulation | 1 | 1 | Dec 2026 est. | NCT06585241 |
Derived from 25 active trials Moderna leads; 25 name an intervention, folding into 21 phased drugs. This is ComplyRx's reading of the registry, not Moderna's own pipeline disclosure.
Moderna trials
The 50 most significant of Moderna's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.
| Trial | Phase | Stability | Status | Enrollment | Est. readout |
|---|---|---|---|---|---|
| Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of AgeNCT05992935mRNA-1403 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 1,407 est. | 22 Sept 2026 |
| A Retrospective Study to Characterize Participants With Propionic AcidemiaNCT05769621 | — | Not yet scored | OngoingRecruiting | 60 est. | 30 Sept 2026 |
| A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and AdultsNCT05164094mRNA-1189 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 867 est. | 5 Oct 2026 |
| A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy ParticipantsNCT05831111mRNA-1195.1 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 482 est. | 13 Oct 2026 |
| A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)NCT05095727mRNA-3745 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 15 est. | 30 Nov 2026 |
| A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy ParticipantsNCT06655870mRNA-0184 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 42 est. | 16 Dec 2026 |
| A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine FormulationsNCT06585241mRNA-1273 Variant-containing Formulation | Phase 4 | Locked · track to reveal | OngoingRecruiting | 1,144 est. | 31 Dec 2026 |
| A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy AdultsNCT07496450mRNA-1018-H5 | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 4,050 est. | 28 Jan 2027 |
| A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and RecipientsNCT06133010mRNA-1647 | Phase 2 | Locked · track to reveal | StoppedWithdrawn | 0 est. | 14 Feb 2027 |
| Nova 301A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute GastroenteritisNCT06592794mRNA-1403 | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 37,864 est. | 15 Feb 2027 |
| A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.NCT05683457mRNA-1647 | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 84 est. | 6 Mar 2027 |
| A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of AgeNCT07478952mRNA-1189 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 120 est. | 15 May 2027 |
| A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)NCT07266558mRNA-1273 | Phase 4 | Locked · track to reveal | OngoingActive, not recruiting | 30,000 est. | 16 Jun 2027 |
| A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy AdultsNCT07764237mRNA-1365 (Profile 2) | Phase 1 | Not yet scored | OngoingRecruiting | 375 est. | 20 Jul 2027 |
| A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid TumorsNCT06880549mRNA-4106 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 42 est. | 3 Aug 2027 |
| Open-Label Study of mRNA-3927 in Participants With Propionic AcidemiaNCT04159103mRNA-3927 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 77 est. | 31 Aug 2027 |
| A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult ParticipantsNCT07737717mRNA-1469 | Phase 1 | Not yet scored | OngoingRecruiting | 84 est. | 30 Sept 2027 |
| A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX)NCT06189053 | — | Not yet scored | OngoingActive, not recruiting | 1,500 est. | 31 Oct 2027 |
| KEYNOTE-603Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid TumorsNCT03313778mRNA-4157 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 161 est. | 21 Nov 2027 |
| A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age)NCT07561294mRNA-1982 | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 366 est. | 9 Nov 2028 |
| A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 YearsNCT06735248mRNA-1195 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 180 est. | 8 Jan 2029 |
| Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT, SPIKEVAX X Injection, SPIKEVAX JN Injection and SPIKEVAX IN PRE-FILLED SYRINGENCT06333704SPIKEVAX Bivalent BA.1 | — | Not yet scored | OngoingActive, not recruiting | 4,207 est. | 29 Mar 2029 |
| A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of AgeNCT07808697mRNA-1283 | Phase 2 | Not yet scored | OngoingNot yet recruiting | 300 est. | 30 Aug 2029 |
| A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 MonthsNCT05743881mRNA-1345 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 186 est. | 31 Aug 2029 |
| A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 StudyNCT05130437mRNA-3927 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 50 est. | 4 Dec 2029 |
| A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple MyelomaNCT07116616mRNA-2808 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 166 est. | 17 Jun 2030 |
| Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid TumorsNCT05533697mRNA-4359 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 361 est. | 18 Feb 2032 |
| An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)NCT03897881mRNA-4157 | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 267 est. | 21 Nov 2032 |
| An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705NCT05295433mRNA-3705 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 56 est. | 2 Apr 2034 |
| A Dose-finding Study to Evaluate mRNA-3210 in Participants With PhenylketonuriaNCT06147856mRNA-3210 | Phase 1 | Locked · track to reveal | StoppedWithdrawn | 0 est. | 10 Aug 2026 |
| A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk AdultsNCT06067230mRNA-1345 | Phase 3 | Locked · track to reveal | Completed | 1,153 est. | 24 Jul 2026 |
| A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing FormulationsNCT07089706mRNA-1283.251 Variant-containing Formulation | Phase 4 | Locked · track to reveal | Completed | 832 est. | 16 Jun 2026 |
| mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)NCT05918250mRNA-2736 | Phase 1 | Locked · track to reveal | StoppedWithdrawn | 0 est. | 27 May 2026 |
| A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated MothersNCT06143046mRNA-1345 | Phase 2 | Locked · track to reveal | Completed | 360 est. | 25 May 2026 |
| A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of AgeNCT05575492mRNA-1647 | Phase 1 | Locked · track to reveal | Completed | 873 est. | 12 May 2026 |
| A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic AcidemiaNCT04899310mRNA-3705 | Phase 1 | Locked · track to reveal | StoppedTerminated | 18 est. | 1 Apr 2026 |
| A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of AgeNCT07117487mRNA-1345 | Phase 3 | Locked · track to reveal | Completed | 507 est. | 27 Mar 2026 |
| A Study of Modified mRNA Vaccines in Healthy AdultsNCT05397223mRNA-1273 | Phase 1 | Locked · track to reveal | Completed | 308 est. | 27 Feb 2026 |
| A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 VaccineNCT04975893mRNA-1647 | Phase 2 | Locked · track to reveal | Completed | 135 est. | 19 Jan 2026 |
| A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of AgeNCT05701800mRNA-1468 | Phase 1 | Locked · track to reveal | StoppedTerminated | 659 est. | 31 Dec 2025 |
| Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of AgeNCT06694389mRNA-1083 | Phase 3 | Locked · track to reveal | Completed | 2,457 est. | 17 Nov 2025 |
| A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy AdultsNCT05606965mRNA-1010 | Phase 2 | Locked · track to reveal | Completed | 172 est. | 13 Nov 2025 |
| A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of AgeNCT05085366mRNA-1647 | Phase 3 | Locked · track to reveal | StoppedTerminated | 7,454 est. | 4 Nov 2025 |
| A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of AgeNCT05436834mRNA-1273.214 | Phase 3 | Locked · track to reveal | Completed | 1,807 est. | 20 Oct 2025 |
| A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of AgeNCT06864143mRNA-1083 Composition 1 Dose A Lot A | Phase 2 | Locked · track to reveal | Completed | 1,320 est. | 13 Oct 2025 |
| A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)NCT06508320mRNA-1083 | Phase 2 | Locked · track to reveal | Completed | 932 est. | 25 Sept 2025 |
| A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of AgeNCT06602024mRNA-1010 | Phase 3 | Locked · track to reveal | Completed | 40,805 est. | 21 Aug 2025 |
| Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced MalignanciesNCT03739931mRNA-2752 | Phase 1 | Locked · track to reveal | Completed | 134 est. | 1 Aug 2025 |
| A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of AgeNCT05127434mRNA-1345 | Phase 2 | Locked · track to reveal | Completed | 36,814 est. | 28 Jul 2025 |
| A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of AgeNCT05995275mRNA-1769 | Phase 1 | Locked · track to reveal | Completed | 351 est. | 8 Jul 2025 |